Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks End Up As Fed and BoJ Decisions Loom

Wed, 27th Apr 2016 15:56

LONDON (Alliance News) - UK shares ended higher Wednesday, with focus on the US Federal Reserve interest rate decision due later today, while investors will have to keep on their toes for the same by the Bank of Japan in the early hours of Thursday.

The FTSE 100 ended up 0.6%, or 35.39 points, at 6,319.91. The FTSE 250 ended up 0.8%, or 138.22 points, at 17,083.71, and the AIM-All Share fell 0.14 points to 729.08.

The Fed monetary policy decision is scheduled for 1900 BST. Economists overwhelmingly expect the central bank to leave its Federal Funds rate target unchanged, but a calmer global macroeconomic backdrop could mean the Fed hints at a rate rise at its next meeting in June.

FOREX.com analyst Fawad Razaqzada also expects the Fed not to announce changes to its monetary policy. However, Razaqzada said investors will scan the statement searching for clues on whether the Fed will hike rates in its next meeting.

"The dollar and other financial markets could...move sharply depending on the language the Federal Open Market Committee uses in the policy statement to describe the health of the world's largest economy, inflation outlook and the likely path of future interest rate changes," Razaqzada said. "This will have indirect impact on some commodities which are priced in the US dollar, such as gold and silver."

Brent oil touched a high of USD47.02 a barrel Wednesday, a level it hasn't seen since mid-November. The North Sea benchmark was adding to its Tuesday gains, when crude prices increased after the American Petroleum Institute reported a draw of nearly 1.1 million barrels in US oil inventories last week.

However, oil prices then retreated Wednesday after the US Energy Information Administration reported a 2 million-barrel climb in crude-oil supplies for the week ended April 22.

Brent was standing at USD46.12 a barrel at the London equities close, higher than the USD45.60 at the same time Tuesday. Meanwhile, gold was quoted at USD1,247.60 an ounce at the close, compared to the USD1,241.76 an ounce on Tuesday.

Stocks in New York were lower at the London equities close, with the Dow 30 down 0.1% and the S&P 500 down 0.2%.

The Nasdaq Composite was down 0.8%, hit by technology giant Apple's drop in profit in the second-quarter, hurt largely by a double-digit revenue decline that reflected weak iPhone sales. Apple reported its results Tuesday after the Wall Street close. Apple shares were down 5.6% at the London close.

In addition to the Fed this week is a Bank of Japan policy decision set for Thursday at 0400 BST. The Japanese central bank will conclude its two-day policy meeting, with analysts widely expecting it to announce a slew of measures to help weaken the yen.

"Given past policy behaviour, we therefore expect the BoJ's chairman Kuroda to be ready to surprise the markets again this year," said Maitland analyst Cebuan Bliss. "'Helicopter money', a consumption subsidy rather of fiscal policy nature, could become a frantic option, as Prime Minister Abe's reform policies have disappointed so far."

Helicopter money refers to a radical form of monetary policy that involves printing large sums of money and distributing it to the public in order to stimulate the economy, like a helicopter scattering euro notes to a crowd.

The UK economy grew at a slower pace, as expected, in the first quarter, preliminary estimates from the Office for National Statistics showed. Gross domestic product grew 0.4%, from a quarter ago, when it expanded 0.6%. This was in line with expectations.

Output increased in the dominant services sector by 0.6%. The other three main industrial groupings within the economy decreased, with production falling by 0.4%, construction output by 0.9% and agriculture by 0.1%.

On a yearly basis, UK GDP grew 2.1% in the first quarter, slightly faster than the expected growth of 2.0%.

Another report from the ONS showed the UK index of services rose 2.5% in February from last year, with the largest contribution coming from distribution, hotels and restaurants and business services and finance. Month-on-month, services output edged up 0.1%, the same pace of growth as in January.

The pound gyrated heavily before and after the economic data, with sterling reaching an intraday high of USD1.4621 prior and then declining to a low of USD1.4550 shortly afterwards. The pound stood at USD1.4544 at the London close compared to USD1.4590 at the close Tuesday.

The euro was quoted at USD1.1308 at the close, slightly lower than USD1.1310 on Tuesday.

In Paris, the CAC 40 index ended up 0.6%, and the DAX 30 in Frankfurt rose 0.4%.

On the London Stock Exchange, Worldpay Group ended up 4.3%, benefiting from an upgrade by UBS to Buy from Neutral. The Swiss bank said Worldpay's exposure to online transactions and significant investment in new value-added services will enable the company to outgrow its peers.

GlaxoSmithKline ended up 2.0% after the drugmaker pleased investors as it clarified its 2016 earnings guidance after an "encouraging" start to the year, implying higher earnings growth than previously indicated, as it continued to see benefits from its three part deal with Novartis AG in 2014.

GlaxoSmithKline's first quarter results beat expectations, helped by strong growth from its vaccines and consumer healthcare businesses, bolstered by the acquisitions it made from Novartis, which offset a small decline to its pharmaceuticals segment following the sale of its oncology business to the Swiss pharmaceutical firm.

Barclays ended up 0.5%, after an intense day for the stock following the lender's first-quarter earnings. The bank said the results showed a core business in rude health even as the bank saw a 25% drop in pretax profit. The stock opened higher, reaching 182.00 pence, its highest level since early-February. However, the shares declined since, closing at 174.80p.

Pretax profit fell to GBP793 million in the three months ended March 31, Barclays said, down from GBP1.06 billion the corresponding quarter a year earlier, with income net of insurance claims down 11% to GBP5.04 billion and credit impairment charges up 15% to GBP443 million. The results were ahead of analyst expectations, reflecting a strong performance in the bank's core business and resilience in its investment banking business.

Emerging-market-focused peer Standard Chartered fell 1.1%, among the worst blue-chip performers, having been downgraded to Sell from Hold by Deutsche Bank. The stock gave back only part of the gains it made Tuesday, when it added 9.8%, reaching its highest level in 2016, after its first-quarter loan impairment charges and capital strength proved better than the market had expected.

In the FTSE 250, Amec Foster Wheeler rose 3.7%, ending among the best performers. The oilfield services company said it has appointed Jonathan Lewis, who has held several senior roles at US giant Halliburton, as its new chief executive, as the company reported a drop in revenue in the first quarter of 2016.

Revenue in the quarter amounted to GBP1.30 billion, 1.5% lower than the GBP1.32 billion booked a year earlier. Revenue was also down 3.1% on a like-for-like basis compared to the previous year. The company's order book stood at GBP6.40 billion at the end of March, compared to GBP6.60 billion at the end of 2015, representing a 3.0% fall.

Societe Generale held a Buy recommendation on the company as the French bank believes this was "a 'normal' but relatively resilient performance in the current environment".

At the other end of the index, McCarthy & Stone dropped 6.1% after funds managed by Anchorage Capital, TPG Special Situations Partners, Goldman Sachs European Special Situations Group and Strategic Value Partners sold 85.0 million shares in the retirement housebuilder, increased from the 75.0 million they had initially planned to sell.

The gross proceeds from the sale to the selling investors were around GBP200.0 million. Following the sale, Anchorage holds a 7.6% stake, TPG a 3.9% stake, Goldman Sachs a 3.9% stake and Strategic Value Partners a 4.2% stake.

In the UK corporate calendar Thursday, Lloyds Banking Group, Taylor Wimpey, WPP, Schroders, Aggreko, Howden Joinery Group, Tullow Oil, Weir Group, Kaz Minerals, Berendsen, NCC Group and Synthomer issue trading statements. Air Partner, Oxford Biomedica, Harvey Nash Group, Camelia, GameAccount Network, U and I Group and Petropavlovsk release full-year results. Avocet Mining publishes a first-quarter production statement.

In the economic calendar, Japan's housing starts data are due at 0600 BST. The UK's nationwide housing prices are due at 0700 BST, while the eurozone's consumer confidence data are at 1000 BST. Germany's consumer price index is due at 1300 BST.

In the US, initial and continuing jobless claims and gross domestic product data are both due at 1330 BST, while the Energy Information Association natural gas storage data are due at 1530 BST.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.